WO2001027071A1 - Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride - Google Patents

Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride Download PDF

Info

Publication number
WO2001027071A1
WO2001027071A1 PCT/GB2000/003847 GB0003847W WO0127071A1 WO 2001027071 A1 WO2001027071 A1 WO 2001027071A1 GB 0003847 W GB0003847 W GB 0003847W WO 0127071 A1 WO0127071 A1 WO 0127071A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphic form
propyl
ethyl
novel polymorphic
amino
Prior art date
Application number
PCT/GB2000/003847
Other languages
French (fr)
Inventor
David Busby
Original Assignee
Smithkline Beecham Laboratories Pharmaceuticals S.A.S.
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001530092A priority Critical patent/JP2003511437A/en
Application filed by Smithkline Beecham Laboratories Pharmaceuticals S.A.S., Smithkline Beecham Plc filed Critical Smithkline Beecham Laboratories Pharmaceuticals S.A.S.
Priority to AU75460/00A priority patent/AU7546000A/en
Priority to CA002386845A priority patent/CA2386845A1/en
Priority to PL00354137A priority patent/PL354137A1/en
Priority to MXPA02003516A priority patent/MXPA02003516A/en
Priority to BR0014591-2A priority patent/BR0014591A/en
Priority to EP00964535A priority patent/EP1218334A1/en
Priority to IL14896600A priority patent/IL148966A0/en
Priority to KR1020027004451A priority patent/KR20020043618A/en
Priority to HU0203582A priority patent/HUP0203582A2/en
Publication of WO2001027071A1 publication Critical patent/WO2001027071A1/en
Priority to NO20021639A priority patent/NO20021639L/en
Priority to HK02109370.9A priority patent/HK1049147A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen;
  • A represents a C1.4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 Ci . ⁇ alkyl groups;
  • R ⁇ represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of the group of R2, R3 and R4 represents nitro the remaining members of the group of R2, R3 and R4 represent hydrogen; X represents a -CO-NH- moiety; and
  • Z represents C2-.4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C ⁇ . alkyl groups.
  • Example 2 of WO 96/13479 is the hydrochloride salt, N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride (hereinafter also referred to as 'the Hydrochloride'), the disclosed melting point of which is 141-2°C.
  • N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride exists in a novel polymorphic form which form is particularly suitable for bulk preparation and handling and is also indicated to have superior formulation properties.
  • This novel polymorphic form can be prepared by an efficient, economic and reproducible process particularly suited to large scale preparation.
  • the novel polymorphic form also has useful pharmaceutical properties and is considered to be a useful anti-arrhythmic agent having combined Class Ill/Class IV anti- arrhythmic properties, therefore showing an improved pharmacological profile over pure class III anti-arrhythmic agents, in particular showing a low proarrhythmic potential, readily restoring the contractile function of the ischaemic myocardium. It is considered to be particularly useful for the treatment of atrial or ventricular cardiac arrhythmias.
  • the present invention provides a novel polymorphic form of N-[3- [[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride (hereinafter also referred to as 'Compound (I)') characterised in that it:
  • the present invention encompasses Compound (I) isolated in a purified form or in an impure form, such as when admixed with other materials, for example the known form of the Hydrochloride or any other material.
  • Compound (I) is in a puried form, especially a crystalline form.
  • the invention also provides a process for preparing the novel polymorphic form of N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride, characterised in that N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4- nitrobenzamide hydrochloride is crystallized from acetonitrile and thereafter the acetonitrile removed, from the product. Preferably the acetonitrile is removed by drying, suitably in vacuo.
  • the crystals are preferably dried at an elevated temperature, for example at 60°C and over an extended period, usually greater than 12 hours for example 36 hours.
  • Crystallisation and any recrystallisation is generally carried out at low to ambient temperature, suitably at ambient temperature.
  • the Hydrochloride is dissolved in acetonitrile at an elevated temperature, for example the reflux temperature of the solvent.
  • crystallisation is initiated by allowing the solution to cool to ambient temperature.
  • Compound (I) is prepared from a solution of the Hydrochloride in acetonitrile at an elevated temperature such as 60°C, allowing the product to crystallise on cooling and thereafter drying the resulting product in vacuo at 60°C. Purification of Compound (I) is also suitably effected by recrystallization of impure Compound (I) using this last mentioned procedure.
  • the Hydrochloride is prepared according to known procedures such as those disclosed in WO 96/13479.
  • the disclosures of WO 96/13479 are incorporated herein by reference.
  • cardiac arrhythmia relates to any variation from the normal rhythm of heart beat, including, without limitation, sinus arrhythmia, premature heartbeat, heartblock, fibrillation, flutter, tachycardia, paroxysmal tachycardia and premature ventricular contractions.
  • the present invention accordingly provides Compound (I) for use as an active therapeutic substance.
  • the present invention provides Compound (I) for use in the treatment of and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders.
  • Compound (I) may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising Compound (I) and a pharmaceutically acceptable carrier therefor.
  • Compound (I) is normally administered in unit dosage form.
  • An amount effective to treat the disorder hereinbefore described depends upon such factors as the efficacy of a Compound (I) chosen, the nature and severity of the disorders being treated and the weight of the mammal.
  • a unit dose will normally contain 0.1 to 500 mg for example 2 to 50 mg, of the compound of the invention.
  • Unit doses will normally be administered once or more than once a day, for example 2,3,4,5 or 6 times a day, more usually 2 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 2500 mg, more usually 1 to 1000 mg, for example 1 to 200 mg, that is in the range of approximately 0.02 to 3 mg/kg/day, more usually 0.1 to 3 mg/kg/day, for example 0.15 to 2 mg/kg/day.
  • the active compound may be administered by any suitable route, e.g. by the oral, parenteral or topical routes.
  • the compound will normally be employed in the form of a pharmaceutical composition in association with a human or veterinary pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.
  • compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices.
  • Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl ⁇ -hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
  • the composition may be in the form of a transdermal ointment or patch for systemic delivery of the compound and may be prepared in a conventional manner, for example, as described in the standard textbooks such as 'Dermatological Formulations' - B.W. Barry (Drugs and the Pharmaceutical Sciences - Dekker) or Harrys Cosmeticology (Leonard Hill Books).
  • compositions may contain further active agents such as anti-hypertensive agents and diuretics.
  • active agents such as anti-hypertensive agents and diuretics.
  • the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
  • the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
  • the present invention further provides a method for the treatment and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Compound (I) to a human or non-human mammal in need thereof.
  • the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
  • Compound (I) may be taken in doses, such as those described above. Similar dosage regimens are suitable for the treatment and/or prophylaxis of non-human mammals.
  • the present invention provides the use of Compound (I) for the manufacture of a medicament for the treatment of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders. No adverse toxicological effects are indicated when Compound (I) is administered in the above mentioned dosage ranges.
  • the Hydrochloride was prepared as disclosed in Example 2 of WO 96/13479. 173g of crude Hydrochloride was dissolved at reflux in 1.3 liter of acetonitrile.
  • a PW1710 X-ray powder diffractometer (Cu X-ray source) was used to generate the spectrum using the following acquisition conditions:
  • Step size 0.005 °2 ⁇
  • the infrared absorption spectrum of a mineral oil dispersion of Compound (I) was obtained using a Perkin-Elmer PE2000 spectrometer at 2 cm -1 resolution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A polymorphic form of N-[3-[[2-(3,4-dimeth0xyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride, a process for preparing such a compound and the use of such a compound in medicine.

Description

POLYMORPHIC N-[3-[[2-(3,4-DIMETHOXYPHENYL) ETHYL] AMINO] PROPYL] -4-NITRO BENZAMIDE HYDROCHLORIDE
This invention relates to a novel pharmaceutical, to a process for the preparation of the pharmaceutical and to the use of the pharmaceutical in medicine. International Patent Application, Publication Number WO 96/13479 discloses certain compounds of formula (A):
Figure imgf000002_0001
(A) or a salt thereof, or a solvate thereof, characterised in that:
Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen;
A represents a C1.4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 Ci .β alkyl groups;
R\ represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of the group of R2, R3 and R4 represents nitro the remaining members of the group of R2, R3 and R4 represent hydrogen; X represents a -CO-NH- moiety; and
Z represents C2-.4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C\. alkyl groups.
Example 2 of WO 96/13479 is the hydrochloride salt, N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride (hereinafter also referred to as 'the Hydrochloride'), the disclosed melting point of which is 141-2°C.
It has now been discovered that N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride exists in a novel polymorphic form which form is particularly suitable for bulk preparation and handling and is also indicated to have superior formulation properties. This novel polymorphic form can be prepared by an efficient, economic and reproducible process particularly suited to large scale preparation.
The novel polymorphic form also has useful pharmaceutical properties and is considered to be a useful anti-arrhythmic agent having combined Class Ill/Class IV anti- arrhythmic properties, therefore showing an improved pharmacological profile over pure class III anti-arrhythmic agents, in particular showing a low proarrhythmic potential, readily restoring the contractile function of the ischaemic myocardium. It is considered to be particularly useful for the treatment of atrial or ventricular cardiac arrhythmias.
Accordingly, the present invention provides a novel polymorphic form of N-[3- [[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride (hereinafter also referred to as 'Compound (I)') characterised in that it:
(i) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or
(ii) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II; and/or (iii) provides an infra red spectrum substantially as illustrated in Figure (I).
The present invention encompasses Compound (I) isolated in a purified form or in an impure form, such as when admixed with other materials, for example the known form of the Hydrochloride or any other material.
Preferably, Compound (I) is in a puried form, especially a crystalline form. The invention also provides a process for preparing the novel polymorphic form of N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride, characterised in that N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4- nitrobenzamide hydrochloride is crystallized from acetonitrile and thereafter the acetonitrile removed, from the product. Preferably the acetonitrile is removed by drying, suitably in vacuo.
The crystals are preferably dried at an elevated temperature, for example at 60°C and over an extended period, usually greater than 12 hours for example 36 hours.
Crystallisation and any recrystallisation is generally carried out at low to ambient temperature, suitably at ambient temperature. Suitably the Hydrochloride is dissolved in acetonitrile at an elevated temperature, for example the reflux temperature of the solvent. Conveniently, crystallisation is initiated by allowing the solution to cool to ambient temperature.
In a preferred form of the process, Compound (I) is prepared from a solution of the Hydrochloride in acetonitrile at an elevated temperature such as 60°C, allowing the product to crystallise on cooling and thereafter drying the resulting product in vacuo at 60°C. Purification of Compound (I) is also suitably effected by recrystallization of impure Compound (I) using this last mentioned procedure.
The Hydrochloride is prepared according to known procedures such as those disclosed in WO 96/13479. The disclosures of WO 96/13479 are incorporated herein by reference.
As used herein, the term "cardiac arrhythmia" relates to any variation from the normal rhythm of heart beat, including, without limitation, sinus arrhythmia, premature heartbeat, heartblock, fibrillation, flutter, tachycardia, paroxysmal tachycardia and premature ventricular contractions.
As mentioned above the compound of the invention has useful therapeutic properties: The present invention accordingly provides Compound (I) for use as an active therapeutic substance.
More particularly, the present invention provides Compound (I) for use in the treatment of and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders.
Compound (I) may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
Accordingly, the present invention also provides a pharmaceutical composition comprising Compound (I) and a pharmaceutically acceptable carrier therefor. Compound (I) is normally administered in unit dosage form. An amount effective to treat the disorder hereinbefore described depends upon such factors as the efficacy of a Compound (I) chosen, the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 0.1 to 500 mg for example 2 to 50 mg, of the compound of the invention. Unit doses will normally be administered once or more than once a day, for example 2,3,4,5 or 6 times a day, more usually 2 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 2500 mg, more usually 1 to 1000 mg, for example 1 to 200 mg, that is in the range of approximately 0.02 to 3 mg/kg/day, more usually 0.1 to 3 mg/kg/day, for example 0.15 to 2 mg/kg/day.
At the above described dosage range, no toxicological effects are indicated for the compounds of the invention. In such treatment, the active compound may be administered by any suitable route, e.g. by the oral, parenteral or topical routes. For such use, the compound will normally be employed in the form of a pharmaceutical composition in association with a human or veterinary pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration. Compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.
Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl ϋ-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
For topical administration, the composition may be in the form of a transdermal ointment or patch for systemic delivery of the compound and may be prepared in a conventional manner, for example, as described in the standard textbooks such as 'Dermatological Formulations' - B.W. Barry (Drugs and the Pharmaceutical Sciences - Dekker) or Harrys Cosmeticology (Leonard Hill Books).
In addition such compositions may contain further active agents such as anti-hypertensive agents and diuretics. As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt. The present invention further provides a method for the treatment and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Compound (I) to a human or non-human mammal in need thereof. Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
In the treatment and/or prophylaxis of arrhythmia and/or ischaemic arrhythmia disorders Compound (I) may be taken in doses, such as those described above. Similar dosage regimens are suitable for the treatment and/or prophylaxis of non-human mammals.
In a further aspect the present invention provides the use of Compound (I) for the manufacture of a medicament for the treatment of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders. No adverse toxicological effects are indicated when Compound (I) is administered in the above mentioned dosage ranges.
The following Examples illustrate the invention but do not limit it in any way.
Example 1
Preparation of a novel polymorphic form N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide, hydrochloride (Compound (I))
The Hydrochloride was prepared as disclosed in Example 2 of WO 96/13479. 173g of crude Hydrochloride was dissolved at reflux in 1.3 liter of acetonitrile.
The solution was then allowed to cool to room temperature over two hours during which time crystallisation occurred. The resulting crystals were filtered off, washed with acetonitrile (1L), dried under vacuum (0.5 Torr) at 60°C for 12 hours and then for a further period of 24 hours under the same conditions (0.5 Torr, 60°C) to afford 125.6 g of Compound (I) m.p. 156°C displaying by HPLC a main peak of 99.8% with the main impurity < 0.1%. Total yield (synthesis + purification) 59.9%.
SPECTROSCOPIC DATA
(A) Solid State NMR
The 90.55MHz 13C CP-MAS NMR spectrum chemical shifts are tabulated in Table I. Data were recorded at ambient temperature and 10 kHz spinning frequency, on a Bruker AMX360WB spectrometer.
Table I
C 3 Chemical shifts (ppm)
28.8 33.4 36.0 49.1 54.6 57.6 107.2 112.7 120.5
126.3 127.9 131.7 137.3 146.8 148.9 164.5
(B) X-Ray Powder Diffraction (XRPD)
A summary of the XRPD angles characteristic of the Compound (I ) is given in Table II.
A PW1710 X-ray powder diffractometer (Cu X-ray source) was used to generate the spectrum using the following acquisition conditions:
Tube anode: Cu
Generator tension: 40 kV
Generator current: 30 mA
Start angle: 3.5 °2Θ
End angle: 35.0 °2Θ
Step size: 0.005 °2Θ
Time per step: 0.25 s
Table II
XRPD Diffraction Angles
Diffraction Angle (°2Θ) 8.7 14.4 18.0 20.7 22.2 22.7 23.9 24.3 24.9 26.6 28.1 29.2 30.8 31.4 32.0 34.0
(C) Infra Red spectrum
The infrared absorption spectrum of a mineral oil dispersion of Compound (I) was obtained using a Perkin-Elmer PE2000 spectrometer at 2 cm-1 resolution.
Figure (I)
Figure imgf000010_0001
40000 3000 2000 1500 1000 450 0 cm-1

Claims

1. A novel polymorphic form of N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride characterised in that it:
(i) provides a solid state nuclear magnetic resonance spectrum containing chemical shifts substantially as represented in Table I; and/or
(ii) provides an X-ray powder refraction (XRPD) pattern substantially as represented in Table II; and/or
(iii) provides an infra red spectrum substantially as illustrated in Figure (I).
2. The novel polymorph according to claim 1, in a purified form.
3. A process for preparing a novel polymorphic form of N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride, characterised in that N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride is crystallized from acetonitrile and therafter the acetonitrile removed from the product.
4. A process according to claim 3, wherein the acetonitrile is removed by drying.
5. A process according to claim 3, or claim 4, wherein the final product is dried at an elevated temperature over an extended period of time.
6. A process according to any one of claims 3 to 5, wherein the novel polymorphic form is prepared from a solution of N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]- 4-nitrobenzamide hydrochloride in acetonitrile at 60°C, the product is allowed to crystallize on cooling and thereafter the resulting product is dried in vacuo at 60°C.
7. A pharmaceutical composition comprising the novel polymorphic form according to claim 1 and a pharmaceutically acceptable carrier therefor.
8. The present invention accordingly provides the novel polymorphic form according to claim 1, for use as an active therapeutic substance.
9. The novel polymorphic form according to claim 1 , for use in the treatment of and/or prophylaxis of cardiac arrhythmia or ischaemic rhythm disorders.
1 1. A method for the treatment and/or prophylaxis of cardiac arrhythmia or ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the novel polymorphic form according to claim 1, to a human or non-human mammal in need thereof.
12. A use of the novel polymorphic form according to claim 1, for the manufacture of a medicament for the treatment of cardiac arrhythmia or ischaemic rhythm disorders.
PCT/GB2000/003847 1999-10-08 2000-10-06 Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride WO2001027071A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR0014591-2A BR0014591A (en) 1999-10-08 2000-10-06 Polymorphic n- [3 - [[2- (3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride
AU75460/00A AU7546000A (en) 1999-10-08 2000-10-06 Polymorphic N-(3-((2-(3,4-dimethoxyphenyl) ethyl) amino) propyl) -4-nitro benzamide hydrochloride
CA002386845A CA2386845A1 (en) 1999-10-08 2000-10-06 Polymorphic n-¬3-¬¬2-(3,4-dimethoxyphenyl) ethyl| amino| propyl| -4-nitro benzamide hydrochloride
PL00354137A PL354137A1 (en) 1999-10-08 2000-10-06 Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride
MXPA02003516A MXPA02003516A (en) 1999-10-08 2000-10-06 Polymorphic n [3 [[2 (3,4 dimethoxyphenyl) ethyl] amino] propyl] 4 nitro benzamide hydrochloride.
JP2001530092A JP2003511437A (en) 1999-10-08 2000-10-06 Polymorphic phase of N- [3-[[2- (3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitrobenzamide hydrochloride
EP00964535A EP1218334A1 (en) 1999-10-08 2000-10-06 Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]- 4-nitro benzamide hydrochloride
HU0203582A HUP0203582A2 (en) 1999-10-08 2000-10-06 Polymorphic n-[3-{[2-(3,4-dimethoxyphenyl)ethyl]amino}propyl]-4-nitro benzamide hydrochloride, process for its preparation, pharmaceutical composition comprising thereof and its use
KR1020027004451A KR20020043618A (en) 1999-10-08 2000-10-06 Polymorphic N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride
IL14896600A IL148966A0 (en) 1999-10-08 2000-10-06 Polymorphic n-[3-[[2-(3,4-dimethoxyp ethyl]amino]propyl]-4-nitro benzamide hydrochloride
NO20021639A NO20021639L (en) 1999-10-08 2002-04-05 Polymorph N- [3 - [[2- (3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitrobenzamide hydrochloride
HK02109370.9A HK1049147A1 (en) 1999-10-08 2002-12-27 Polymorphic n-[3[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923933.7A GB9923933D0 (en) 1999-10-08 1999-10-08 Novel pharmaceutical
GB9923933.7 1999-10-08

Publications (1)

Publication Number Publication Date
WO2001027071A1 true WO2001027071A1 (en) 2001-04-19

Family

ID=10862442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003847 WO2001027071A1 (en) 1999-10-08 2000-10-06 Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride

Country Status (18)

Country Link
EP (1) EP1218334A1 (en)
JP (1) JP2003511437A (en)
KR (1) KR20020043618A (en)
CN (1) CN1384817A (en)
AU (1) AU7546000A (en)
BR (1) BR0014591A (en)
CA (1) CA2386845A1 (en)
CZ (1) CZ20021189A3 (en)
GB (1) GB9923933D0 (en)
HK (1) HK1049147A1 (en)
HU (1) HUP0203582A2 (en)
IL (1) IL148966A0 (en)
MX (1) MXPA02003516A (en)
NO (1) NO20021639L (en)
PL (1) PL354137A1 (en)
TR (1) TR200200949T2 (en)
WO (1) WO2001027071A1 (en)
ZA (1) ZA200202679B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520803A (en) * 2002-01-09 2005-07-14 エミスフェアー・テクノロジーズ・インク Polymorph of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2091910E (en) * 2006-12-06 2014-11-18 Conatus Pharmaceuticals Inc Crystalline forms of (3 s) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-oxopenta noic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013479A1 (en) * 1994-10-26 1996-05-09 Smithkline Beecham Laboratoires Pharmaceutiques Nitro-benzamides useful as anti-arrhythmic agents
WO1998043947A1 (en) * 1997-03-27 1998-10-08 Smithkline Beecham Plc Nitro-benzamide useful as anti-arrhythmic agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013479A1 (en) * 1994-10-26 1996-05-09 Smithkline Beecham Laboratoires Pharmaceutiques Nitro-benzamides useful as anti-arrhythmic agents
WO1998043947A1 (en) * 1997-03-27 1998-10-08 Smithkline Beecham Plc Nitro-benzamide useful as anti-arrhythmic agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520803A (en) * 2002-01-09 2005-07-14 エミスフェアー・テクノロジーズ・インク Polymorph of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
US7893297B2 (en) 2002-01-09 2011-02-22 Emisphere Technologies, Inc. Amorphous sodium 4-[4-chloro-2-hydroxybenzoyl)amino]butanoate

Also Published As

Publication number Publication date
PL354137A1 (en) 2003-12-29
JP2003511437A (en) 2003-03-25
EP1218334A1 (en) 2002-07-03
CA2386845A1 (en) 2001-04-19
CZ20021189A3 (en) 2002-09-11
NO20021639L (en) 2002-05-30
MXPA02003516A (en) 2004-09-10
ZA200202679B (en) 2003-05-28
BR0014591A (en) 2002-06-11
GB9923933D0 (en) 1999-12-08
CN1384817A (en) 2002-12-11
IL148966A0 (en) 2002-11-10
NO20021639D0 (en) 2002-04-05
KR20020043618A (en) 2002-06-10
HK1049147A1 (en) 2003-05-02
TR200200949T2 (en) 2002-08-21
HUP0203582A2 (en) 2004-03-01
AU7546000A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
US5958951A (en) Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
WO1992017473A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
ES2218146T3 (en) DERIVED FROM TIAZOLIDINADIONA AND ITS USE AS AN ANTIDIABETIC.
EP1218334A1 (en) Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]- 4-nitro benzamide hydrochloride
EP0906309B1 (en) Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
EP1173437B1 (en) Thiazolidinedione derivative and its use as antidiabetic
AP1205A (en) Nitro-benzamide useful as anti-arrhythmic agents.
WO2001027072A1 (en) Hydrated n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride and its use in pharmaceutical compositions
EP0719263B1 (en) Heterocyclic carboxamide derivatives with antiarrhythmic activity
US20010056207A1 (en) Nitro-benzamide useful as anti-arrhythmic agent
KR100491636B1 (en) Modified form of the r(-)-n-[4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
CZ341899A3 (en) Nitrobenzamide suitable as anti-arrhythmic preparation
CA2257931C (en) Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
MXPA99008872A (en) Nitro-benzamide useful as anti-arrhythmic agent
WO1996027595A1 (en) Heterocyclycarboxamides and other compounds for the treatment of the cardiac arrhythmias

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00395/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 75460/00

Country of ref document: AU

Ref document number: 148966

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 530092

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000964535

Country of ref document: EP

Ref document number: 10089743

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PV2002-1189

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002/02679

Country of ref document: ZA

Ref document number: PA/a/2002/003516

Country of ref document: MX

Ref document number: 200202679

Country of ref document: ZA

Ref document number: 518188

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020027004451

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2386845

Country of ref document: CA

Ref document number: 008139903

Country of ref document: CN

Ref document number: 2002/00949

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1020027004451

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000964535

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1189

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 518188

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000964535

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 518188

Country of ref document: NZ